Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Ann Oncol. 2019 Dec 1;30(12):1985-1991. doi: 10.1093/annonc/mdz407.
Ann Oncol. 2019.
PMID: 31584608
Free article.
Clinical Trial.